In the preceding three months, 4 analysts have released ratings for Lyell Immunopharma (NASDAQ:LYEL), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 0 | 0 | 3 | 1 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 1 | 1 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $1.0, a high estimate of $1.00, and a low estimate of $1.00. Experiencing a 55.56% decline, the current average is now lower than the previous average price target of $2.25.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst...
Login or create a forever free account to read this news
Sign up/Log in